Working... Menu
Trial record 31 of 36 for:    Acerta Pharma

Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02570711
Recruitment Status : Terminated (Sponsor Decision)
First Posted : October 7, 2015
Last Update Posted : June 24, 2016
Information provided by (Responsible Party):
Acerta Pharma BV

Brief Summary:
To evaluate the Safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with metastatic pancreatic cancer using standard response criteria

Condition or disease Intervention/treatment Phase
Metastatic Pancreatic Cancer Drug: ACP-196 and Nab-paclitaxel and gemcitabine Drug: Nab-paclitaxel and gemcitabine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : October 2015
Estimated Primary Completion Date : May 2017

Arm Intervention/treatment
Experimental: Regimen 1
ACP-196 and nab-paclitaxel and gemcitabine
Drug: ACP-196 and Nab-paclitaxel and gemcitabine
Experimental: Regimen 2
Nab-paclitaxel and gemcitabine
Drug: Nab-paclitaxel and gemcitabine

Primary Outcome Measures :
  1. The overall response rate (ORR) of ACP-196 plus nab-paclitaxel/gemcitabine compared with nab-paclitaxel/gemcitabine in patients with previously untreated metastatic pancreatic cancer [ Time Frame: 13 Cycles (each cycles is 28 days) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women ≥ 18 years of age.
  • ECOG performance status of 0 or 1.
  • Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.
  • No previous radiotherapy, chemotherapy or investigational therapy for the treatment of metastatic disease. Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present.

Exclusion Criteria:

  • Prior malignancy (other than pancreatic cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years.
  • Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  • Biliary obstruction or presence of a percutaneous biliary drain. Note: Subjects with endobiliary stents may participate as long the enrollment criterion relating to serum bilirubin concentration is met.
  • Breastfeeding or pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02570711

Layout table for location information
United States, Texas
International Cancer Center
Houston, Texas, United States, 77030
MD Anderson
Houston, Texas, United States
Sponsors and Collaborators
Acerta Pharma BV

Layout table for additonal information
Responsible Party: Acerta Pharma BV Identifier: NCT02570711     History of Changes
Other Study ID Numbers: ACE-ST-004
First Posted: October 7, 2015    Key Record Dates
Last Update Posted: June 24, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs